Study of Ibrutinib in Subjects With Acute Myeloid Leukemia

NCT02351037 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

36

Enrollment

INDUSTRY

Sponsor class

Stopped Study data do not support development in AML.

Conditions

Acute Myeloid Leukemia (AML)

Interventions

DRUG: Ibrutinib
DRUG: Ibrutinib + LD-AraC
DRUG: Ibrutinib+Azacitidine

Sponsor

Pharmacyclics LLC.